- EPA Earmarks $3 Billion to Replace Lead Pipes Nationwide
- Johnson & Johnson Will Pay $6.5 Billion to Settle Talc Ovarian Cancer Lawsuits
- No Sign of Bird Flu in Ground Beef, USDA Says
- U.S. Maternal Deaths Declined in 2022
- Economy, Election Spur Rising Anxiety Among Americans in 2024
- Day Care Pick-Up Often Involves Sugary Snacks, Study Finds
- A Third of Young Adults Still Believe ‘Tan Is Healthier’ Myth: Survey
- MRNA Vaccine Fights Deadly Brain Tumor in Small Trial
- AI Won’t Replace ER Doctors Anytime Soon: Study
- Sleep Apnea Linked With Late-Life Epilepsy
Idelvion Approved for Hemophilia B
Idelvion has been approved by the U.S. Food and Drug Administration to replace a deficient blood clotting factor among people with hemophilia B.
The product — which has the generic name of “coagulation Factor IX, albumin fusion protein” — is created using recombinant DNA technology that links the blood clotting protein known as Factor IX to another blood protein, albumin. This technology allows the protein to last longer when given intravenously, the FDA said in a news release.
People with the rare genetic disorder hemophilia B are prone to recurring episodes of serious bleeding, primarily into the joints. Most people with the disorder are male, although it occasionally affects females, the agency said.
The new product is meant to control bleeding episodes and to reduce their frequency. It can also be given to prevent bleeding after surgery, the FDA said.
Idelvion was evaluated in clinical studies involving 90 adults and children, ages 1 year to 61. No safety concerns were identified during the studies, and the most common side effect was headache, the agency said.
The product is manufactured by CSL Behring, based in King of Prussia, Penn.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.